MedTrace Logo

Psychometric Properties of the Therapy-Related Symptom Checklist-Children

NCT06488456 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-02-28

No results posted yet for this study

Summary

Diagnosis and treatment of childhood cancers is an exhausting process that affects both children and their caring parents physically and mentally. While the survival rate in childhood cancers was 28% in the 1960s, this rate has increased up to 80% with the developments in treatment methods. Although the main methods used in cancer treatment today are surgical treatment, radiotherapy, and immunotherapy, the main component of cancer treatment is chemotherapy. Improvements in chemotherapy protocols have increased survival; however, the use of high-dose chemotherapy may increase the frequency and severity of symptoms that may be seen in children. Therefore, diagnosis and management of treatment-related symptoms in the pediatric population receiving chemotherapy treatment as soon as possible is of vital importance as it will significantly affect the quality of life of children. In this context, this study aimed to add to the national literature by conducting a Turkish validity and reliability study of a checklist suitable for the use of health professionals in clinics for monitoring the side effects of chemotherapy. In the study, validity and reliability tests will be performed for intercultural scale adaptation.

Conditions

  • Pediatric Leukemia, Acute Myeloid
  • Pediatric ALL

Interventions

OTHER

TRSC-C

Data were collected using TRSC-C

Sponsors & Collaborators

  • Ege University

    lead OTHER

Principal Investigators

  • Seda Ardahan Sevgili, PhD · Ege University

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-12-01
Completion
2025-02-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06488456 on ClinicalTrials.gov